Ward LM, Kinnett K, Bonewald L. Proceedings of a Parent Project Muscular Dystrophy Bone Health Workshop: Morbidity due to osteoporosis in DMD: The Path Forward May 12-13, 2016, Bethesda, Maryland, USA. Neuromuscular Disord 2018;28:64-76
A meeting with 48 opinion leaders, research experts and clinicians on Duchenne muscular dystrophy (DMD) bone biology from Canada and USA (15 states/provinces) was held in Bethesda, Maryland, USA from May 12 to May 13, 2016 to discuss the way forward in the research and management of bone health in DMD. The devastating effects of dystrophin loss in DMD have been the focus of both basic and clinical research for decades. However, less attention has been given to the effects of DMD and that of the major therapy for DMD, glucocorticoids (GC), on bone health. While the effects of GC on the preservation of muscle function in DMD are clear, a significant detrimental side effect is an increased risk of fractures and the clinical consequences of bone fragility. The goals of this meeting were to review the extent of bone morbidity due to osteoporosis and current management guidelines, to discuss the known and potential mechanisms of bone disease, and to provide recommendations and direction for future basic, translational and clinical research with a focus on DMD bone health. This manuscript presents a summary of the meeting’s proceedings.